Skip to content

Author

Ana Gutiérrez Casbas

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Ulcerative colitis, but not Crohn’s disease, displays demographically and clinically driven mucosal immune heterogeneity: implications for patient stratification

Background Inflammatory bowel disease (IBD) encompasses Crohn’s disease (CD) and ulcerative colitis (UC), two conditions with distinct immunopathological profiles despite shared inflammatory pathways. Comparative mucosal and systemic immune characterisation across disease subtypes and clinical variables remains limited...

Á. de Prado, I. Soleto, C. G. de Castro et al. · 0 citations
Review Oct 2026

EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease.

OBJECTIVE Much of the available real-world evidence on the gut-selective α4β7 integrin antibody vedolizumab comes from patients with repeated failure of anti-tumour necrosis factor-α (anti-TNFα) agents and other treatments. The EVOLVE-IBERIA study is aimed to generate additional real-world evidence for vedolizumab and...

J. F. Muñoz, Ana Gutiérrez Casbas, C. Rodríguez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.